Ho-Yun Kim1, Ji-Eun Lee2, Ha-Na Oh3, Ju-Whan Song4, Sang-Youp Han5, Jong-Soo Lee6,7. 1. Department of Ophthalmology, Maryknoll Medical Center, Busan 48972, South Korea. 2. Department of Ophthalmology, Pusan National University Yangsan Hospital, Yangsan 50612, South Korea. 3. Department of Ophthalmology, Inje University Baek Hospital, Busan 47392, South Korea. 4. Department of Ophthalmology, Kosin University hospital, Busan 49267, South Korea. 5. Sungmo Eye Clinic, Busan 48064, South Korea. 6. Department of Ophthalmology, Pusan National University Hospital, Busan 49241, South Korea. 7. Medical Research Institute, Pusan National University Hospital, Busan 49241, South Korea.
Abstract
AIM: To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD). METHODS: In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% CsA and preservative free sodium hyaluronate vehicle (experimental group, n=74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, n=32 eyes). They were evaluated at baseline and 1, 2, and 3mo for subjective symptoms and objective signs including tear film break-up time (tBUT), Schirmer test, corneal staining (CS) score, lid margin telangiectasia (LMT), meibomian gland secretion (MGS), and conjunctival injection (CI). RESULTS: In the short-term treatment, the experimental group showed a statistically significant improvement in the ocular surface disease index (OSDI; P<0.001), tBUT (P=0.004), Schirmer test score (P=0.008) and LMT (P=0.021) by repeated measure ANOVA. Additionally, mean changes from baseline in OSDI (P<0.001), tBUT (P=0.001), Schirmer test score (P=0.029), CS score (P=0.047), LMT (P=0.002), CI (P=0.030) were improved better in the experimental group than in the control group at 3mo. However, there was no significant difference between the two groups in MGS (P=0.67). CONCLUSION: In dry eyes with MGD, 0.05% CsA improves the tear film stability as well as subjective ocular discomfort, and is effective in controlling lid margin inflammation.
AIM: To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD). METHODS: In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% CsA and preservative free sodium hyaluronate vehicle (experimental group, n=74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, n=32 eyes). They were evaluated at baseline and 1, 2, and 3mo for subjective symptoms and objective signs including tear film break-up time (tBUT), Schirmer test, corneal staining (CS) score, lid margin telangiectasia (LMT), meibomian gland secretion (MGS), and conjunctival injection (CI). RESULTS: In the short-term treatment, the experimental group showed a statistically significant improvement in the ocular surface disease index (OSDI; P<0.001), tBUT (P=0.004), Schirmer test score (P=0.008) and LMT (P=0.021) by repeated measure ANOVA. Additionally, mean changes from baseline in OSDI (P<0.001), tBUT (P=0.001), Schirmer test score (P=0.029), CS score (P=0.047), LMT (P=0.002), CI (P=0.030) were improved better in the experimental group than in the control group at 3mo. However, there was no significant difference between the two groups in MGS (P=0.67). CONCLUSION: In dry eyes with MGD, 0.05% CsA improves the tear film stability as well as subjective ocular discomfort, and is effective in controlling lid margin inflammation.
Authors: Gerd Geerling; Christophe Baudouin; Pasquale Aragona; Maurizio Rolando; Kostas G Boboridis; José M Benítez-Del-Castillo; Yonca A Akova; Jesús Merayo-Lloves; Marc Labetoulle; Martin Steinhoff; Elisabeth M Messmer Journal: Ocul Surf Date: 2017-01-27 Impact factor: 5.033
Authors: Henry D Perry; Renée Solomon; Eric D Donnenfeld; Alicia R Perry; John R Wittpenn; Herb E Greenman; Howard E Savage Journal: Arch Ophthalmol Date: 2008-08
Authors: Sang Yeop Lee; Soo Jung Han; Sang Min Nam; Sang Chul Yoon; Ji Min Ahn; Tae-Im Kim; Eung Kweon Kim; Kyoung Yul Seo Journal: Am J Ophthalmol Date: 2013-06-07 Impact factor: 5.258